脂必泰胶囊联合瑞舒伐他汀钙片治疗糖尿病合并颈动脉粥样硬化的临床研究  

Clinical study on treating diabetes mellitus complicated with carotid artery atherosclerosis with Zhibitai capsule combined with Resuvastatin Calcium tablets

作　　者：齐小峰 张敬 王莉莉 魏伟 Qi Xiaofeng;Zhang Jing;Wang Lili;Wei Wei(Department of Endocrinology,Zhengzhou Yihe Hospital,Zhengzhou,Henan 450018,China;Department of Endocrinology,Zhengzhou People's Hospital,Zhengzhou,Henan 450018,China)

机构地区：[1]郑州颐和医院内分泌科,河南郑州450018 [2]郑州人民医院内分泌科,河南郑州450003

出　　处：《齐齐哈尔医学院学报》2023年第23期2232-2235,共4页Journal of Qiqihar Medical University

摘　　要：目的探讨脂必泰胶囊联合瑞舒伐他汀钙片在糖尿病合并颈动脉粥样硬化(DM-CAS)的临床应用效果。方法选择2021年2月—2023年7月本院收治的80例DM-CAS患者为研究对象,根据随机信封法分为观察组和对照组两组,每组各40例。两组均予西格列汀二甲双胍片进行基础治疗,对照组予瑞舒伐他汀钙片治疗,观察组予脂必泰胶囊联合瑞舒伐他汀钙片治疗,治疗3个月。观察两组治疗前、后血脂代谢指标[高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三脂(TG)]、内皮功能[内皮素-1(ET-1)、一氧化氮(NO)]、斑块情况[斑块数量、面积、Crouse积分及内中膜厚度(IMT)],观察治疗期间不良反应发生情况。结果治疗3个月,两组LDL-C、TC、TG、HDL-C水平较治疗前改善,且观察组优于对照组(P<0.05);两组内皮功能(NO、ET-1)水平较治疗前改善,且观察组改善程度优于对照组(P<0.05);两组IMT、斑块数量、斑块面积、斑块Crouse积分均较治疗前降低,且观察组低于对照组(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论脂必泰胶囊联合瑞舒伐他汀钙片治疗DM-CAS效果较好,可有效控制血脂水平、改善内皮功能、稳定患者斑块,且安全性好。Objective To investigate the clinical application effect of Zhibitai capsule combined with rosuvastatin calcium tablet in the treatment of patients suffering from diabetes mellitus combined with carotid artery atherosclerosis(DM-CAS).Methods This study prospectively included 80 DM-CAS patients who were admitted to the hospital from February 2021 to July 2023 as the study subjects.According to the random envelope method,they were divided into observation group and control group,40 cases in each group.Both groups received basic treatment with Sitagliptin Metformin tablets,the control group received treatment with rosuvastatin calcium tablets,and the observation group received treatment with Zhibitai Capsules combined with rosuvastatin calcium tablets for 3 months.The blood lipid metabolism indicators[high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),triglycerides(TG)],endothelial function[endothelin-1(ET-1),nitric oxide(NO)],plaque condition[plaque number,area,Crouse score,and intima media thickness(IMT)]of the two groups were observed before and after treatment,and the occurrence of adverse reactions during the treatment period were observed.Results After 3 months of treatment,the levels of LDL-C,TC,TG,HDL-C in both groups improved compared with those before treatment,and the improvement degree of the observation group was better than that of the control group(P<0.05).The levels of endothelial function(NO,ET-1)in both groups improved compared to those before treatment,and the improvement degree in the observation group was better than that in the control group(P<0.05).The IMT,plaque number,plaque area,and plaque Crouse score of both groups decreased compared to those before treatment,and the observation group was lower than the control group(P<0.05).There was no statistical significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusions The combination of Zhibitai capsules and rosuvastatin calcium tablets has a

关 键 词：糖尿病 颈动脉粥样硬化 脂必泰胶囊 瑞舒伐他汀钙片 

分 类 号：R587.1[医药卫生—内分泌]